A 54 Week, Extension to the Double-blind, Multicenter, Multifactorial, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Valsartan (160 mg and 320 mg) and Amlodipine (10 mg) Combined and Alone in Hypertensive Patients

NCT00170976 Phase 3 COMPLETED

A ONE YEAR SAFETY STUDY FOR PATIENTS WHO COMPLETE STUDY VAA489A2307.

Details

Lead sponsor	Novartis
Phase	Phase 3
Status	COMPLETED
Enrolment	403
Start date	2004-04
Completion	2005-06

Conditions

• HYPERTENSION

Interventions

• valsartan + amlodipine

Primary outcomes

• Adverse events and serious adverse events at each study visit for 6 or 12 months

Countries

Germany, Switzerland